Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$29 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0552
E

Failure to Obtain Informed Consent for Psychotropic Medications

Harrisburg, Pennsylvania Survey Completed on 03-12-2026

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to inform residents or their representatives of the risks and benefits of psychotropic medications and did not obtain consent prior to administering these medications for three residents reviewed. The facility’s Psychoactive Medication Policy, last reviewed on April 30, 2025, did not contain any expectation for obtaining consent before starting psychoactive medications. For one resident with major depressive disorder and dementia, physician orders showed Trazodone 75 mg three times daily for depression starting February 13, 2026, and Lorazepam 0.5 mg twice daily for anxiety starting December 16, 2025. The care plan documented psychotropic drug use beginning July 9, 2024, but the medical record contained no documentation of an explanation of risks and benefits or consent for these medications. The DON confirmed that appropriate notifications were not made prior to starting psychotropic medications for this resident. Another resident with dementia and depression had multiple psychotropic medication orders, including quetiapine, Rexulti, mirtazapine, and trazodone, with corresponding care plan focuses on antipsychotic and antidepressant use. However, the medical record lacked documentation of any explanation of the risks and benefits of these psychotropic medications or consent from the resident or representative, and the DON and Regional Director of Clinical Services stated there were no psychotropic medication consents for this resident. A third resident with bipolar disorder, anxiety disorder, depression, and dementia had orders for aripiprazole, bupropion, and escitalopram, and a care plan focus on psychotropic drug use including antidepressant, antipsychotic, and mood stabilizer medications. Review of this resident’s record also failed to show any explanation of risks and benefits or consent for psychotropic medication use, and staff confirmed that no psychotropic medication consents were available. These findings were cited under 28 Pa. Code 201.29(a) Resident rights and 28 Pa. Code 211.12(d)(1)(3)(5) Nursing services.

Long-term care team reviewing survey readiness and plan of correction

We Help Long-Term Care Teams Stay Survey-Ready

We process and analyze inspection reports and plan of correction using AI to extract insights and trends so providers can improve care quality and stay ahead of compliance risks.

Discover our solutions:

An unhandled error has occurred. Reload 🗙